Learn how biologic therapies for psoriasis work, the difference between single and dual inhibitors, and how dermatologists choose the right treatment for the individual.

Phase 1 studies showed that one shot of ORKA-001 lasted long enough to allow dosing twice-a-year—or even once-a-year.

Add Yahoo as a preferred source to see more of our stories on Google. A Johnson & Johnson banner is displayed on the front of the NYSE in New York (Reuters) -Johnson & Johnson said on Friday its ...

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight The psoriasis clinical trial analysis report delivers important insights into ongoing ...

Biologic drugs used to treat psoriasis were associated with lower risks for certain ocular diseases, including keratitis and ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

TACONY (WPVI) -- Psoriasis shows on the skin, but it's a disease which goes a lot deeper, and is linked to serious health problems. In recent years, newer targeted drugs are making a difference and ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...

Medicare coverage for psoriasis drugs depends on the type of Medicare plan you have and the drug your doctor prescribes. But if your doctor considers a drug medically necessary, Medicare may cover it.

One of the more serious side effects from immune checkpoint inhibitor (ICI) therapies for cancer is new-onset or worsened autoimmune diseases. Clinicians have been concerned that conventional ...

Johnson & Johnson failed to prove that the launch of a biosimilar version to its psoriasis drug Stelara will harm the company ...